Welcome to our dedicated page for Concert Pharm news (Ticker: CNCE), a resource for investors and traders seeking the latest updates and insights on Concert Pharm stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Concert Pharm's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Concert Pharm's position in the market.
Concert Pharmaceuticals (NASDAQ: CNCE) will present clinical data on CTP-543 for treating alopecia areata at the 29th EADV Virtual Congress from October 29-31, 2020. The presentation will share results from an ongoing open-label extension study, focusing on the long-term safety and treatment effects of CTP-543. This oral selective inhibitor of Janus kinases has received Breakthrough Therapy and Fast Track designations from the FDA. The Company plans to initiate Phase 3 evaluation of CTP-543 in Q4 2020.
Concert Pharmaceuticals (NASDAQ: CNCE) has completed patient enrollment for its Phase 2 clinical trial of CTP-692, an adjunctive treatment for schizophrenia. The trial aims to assess the drug's effectiveness in improving primary symptom domains, including both positive and negative symptoms, as well as cognitive function. A total of 325 patients were randomized to receive varying doses of CTP-692 or a placebo. Topline data is expected in Q1 2021, with a focus on changes in the Positive and Negative Syndrome Scale (PANSS) total score after 12 weeks of treatment.